Founded in 2020, SciNeuro Pharmaceuticals is building a pipeline of drug programs aimed at proteins implicated in neurodegeneration, including beta amyloid and LRRK2. The company’s strategy is to attack a range of disease pathways to improve treatment options for conditions like Alzheimer’s and Parkinson’s, areas that historically suffer from low drug-development success rates. Recent scientific progress is supported by a $5 million non-dilutive research grant from The Michael J. Fox Foundation for Parkinson’s Research. The new capital will be used to advance pre-clinical and early clinical studies across its portfolio. In parallel, the company has strengthened its leadership team by appointing Hogan Wan, formerly of Ascentage Pharma, as chief financial officer to steer corporate finance and potential IPO preparation. SciNeuro positions itself alongside other Arch-backed neuroscience startups, leveraging Arch’s deep experience in the sector. No commercial revenue has been disclosed, and operating metrics such as cash runway or headcount were not provided.

Total raised

$153M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2025